Literature DB >> 11166154

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

G Krähn1, U Leiter, P Kaskel, M Udart, J Utikal, G Bezold, R U Peter.   

Abstract

The receptor tyrosine kinases (RTKs) epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 are involved in the pathogenesis of multiple human malignant neoplasias. However, their role in the carcinogenesis of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) remains to be elucidated. In order to further define the role of these RTKs, 56 human skin tissue samples of normal skin, BCC and SCC were studied by conventional and differential and quantitative reverse transcriptase-polymerase chain reaction (rtPCR). EGFR and HER3 were predominantly expressed in the BCCs and SCCs, while HER2 was ubiquitously expressed. HER4 was not expressed in any sample. Since in vitro studies have provided compelling evidence that heterodimer formation of these receptors are associated with different signal transduction processes, coexpression patterns might be decisive for the induction and maintenance of a malignant phenotype. These results confirm this concept: isolated HER2 expression and EGFR/HER2 were predominantly found in normal skin, while HER2/HER3 and the triple expression of EGFR/HER2/HER3 were seen more frequently in the BCCs and SCCs compared with normal skin (50% and 40% compared with 26%, respectively). The activation of HER3, in addition to EGFR and HER2, might therefore be associated with the malignant phenotype. However, due to the small numbers in this study, further confirmation of the patterns is needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166154     DOI: 10.1016/s0959-8049(00)00364-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  25 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

Review 2.  Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.

Authors:  M Nikanjam; P R Cohen; S Kato; J K Sicklick; R Kurzrock
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

3.  Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.

Authors:  Kaoru Kiguchi; Takuya Kitamura; Tricia Moore; Mohammad Rumi; Hsiang-Chun Chang; Devon Treece; Lynnsie Ruffino; Kevin Connolly; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-03

4.  ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.

Authors:  Maik Dahlhoff; Matthias Schäfer; Sukalp Muzumdar; Christian Rose; Marlon R Schneider
Journal:  Mol Oncol       Date:  2015-07-03       Impact factor: 6.603

5.  Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Authors:  Justin G Madson; David T Lynch; Jessica Svoboda; Rebecca Ophardt; Jodi Yanagida; Sumanth K Putta; Andrew Bowles; Carol S Trempus; Raymond W Tennant; Laura A Hansen
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

6.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.

Authors:  Chi-Hong B Chen; George A Chernis; Van Q Hoang; Ralf Landgraf
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

7.  Expanding the utility of beta-galactosidase complementation: piece by piece.

Authors:  Ann-Marie Broome; Nihir Bhavsar; Gopalakrishnan Ramamurthy; Gail Newton; James P Basilion
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

8.  Systemic therapy for inoperable and metastatic basal cell cancer.

Authors:  Leslie A Fecher
Journal:  Curr Treat Options Oncol       Date:  2013-06

9.  EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

Authors:  Jian Ming Xu; Yu Han; Hai Qing Duan; E Mei Gao; Yang Zhang; Xiao Qing Liu; Jing Sheng Zhang; Luca Toschi; Domenico Galetta; Amalia Azzariti; Angelo Paradiso
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-20       Impact factor: 4.553

10.  AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.

Authors:  Arianna L Kim; Jung Ho Back; Yucui Zhu; Xiuwei Tang; Nathan P Yardley; Katherine J Kim; Mohammad Athar; David R Bickers
Journal:  Cancer Prev Res (Phila)       Date:  2016-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.